Faster Is The New Normal In Oncology Drug Development

August 23, 2017

The days when oncology drugs advanced foreseeably from Phase I to Phase II to Phase III clinical trials, with predictable pauses for regulatory reviews and refinement of trial designs, are gone.

A new, maverick model of seamless drug development is emerging, one in which a first-in-human trial can morph, without pause, into a pivotal efficacy trial. Due to competitive pressures, companies may need to change the way they develop oncology drugs, fast.

While seizing opportunities for efficiency and smarter advancement decisions, companies need to limit their exposure to safety and other risks. At PAREXEL, we advise companies to follow five risk-mitigation strategies to produce data-rich trials, better teamwork and more regulatory interaction.

Previous Flipbook
Beyond Compliance: Using Quality Metrics To Gain Competitive Advantage
Beyond Compliance: Using Quality Metrics To Gain Competitive Advantage

Smart companies realize that improving data systems and quality metrics is not simply a matter of complianc...

Next Flipbook
Leveraging FDA's Accelerated Pathways For Market Advantage
Leveraging FDA's Accelerated Pathways For Market Advantage

Successfully leverage the FDA’s accelerated pathways to reach the market more quickly and enhance commercia...